GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology.

نویسندگان

  • Ilan Tur-Kaspa
  • Diego Ezcurra
چکیده

BACKGROUND Gonadotropin-releasing hormone (GnRH) analogues are used routinely to prevent a premature luteinizing hormone (LH) surge in women undergoing assisted reproductive technology (ART) treatments. In contrast to GnRH agonists, antagonists produce rapid and reversible suppression of LH with no initial flare effect. OBJECTIVE To review the role of cetrorelix, the first GnRH antagonist approved for the prevention of premature LH surges during controlled ovarian stimulation in modern ART. METHOD A review of published literature on cetrorelix. RESULTS Both multiple- and single-dose cetrorelix protocols were shown to be at least as effective as long GnRH agonist regimens for pituitary suppression in Phase II/III clinical trials. Furthermore, cetrorelix co-treatment resulted in similar live birth rates but a shorter duration of gonadotropin stimulation, a lower total gonadotropin dose requirement and lower incidence of ovarian hyperstimulation syndrome compared with long agonist regimens. A single-dose cetrorelix protocol further decreased the number of injections required. Preliminary studies have also produced promising data on the use of cetrorelix in modified ART protocols, such as frozen embryo transfer and donor oocyte recipient cycles. CONCLUSION Cetrorelix offers a potential therapeutic alternative to GnRH agonists during controlled ovarian stimulation and has become an integral part of modern, patient-friendly reproductive medicine.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

P-228: Low Dose HCG Adjunct to r-hFSH/GnRH Antagonist for Controlled Ovarian Stimulation in Assisted Reproductive Technology: A Prospective and Randomized Trial

Background: Deep suppression of LH in GnRH antagonist cycles may have detrimental effect on reproductive out come. It was hypnotized that adding LH activity via the administration of low dose HCG in late follicular phase shortened the duration of stimulation, decreased consumption of gonadotropin and increased estrogen levels. This study was designed to evaluate the effect of adding low dose HC...

متن کامل

I-26: The Role of Stimulating Agents and Protocols in Prevention of Severe OHSS

The goal of ovarian Stimulation for assisted reproductive technologies (ART) is obtaining multifollicular growth ovarian hyper stimulation syndrome (OHSS) is one of the most Severe and also potentially Life-threatening complications, which happens in 1-10% of IVF cycles. The most common risk factors which are related to OHSS are polycystic ovarian syndrome (PCOS), younger age, high preovulatory...

متن کامل

Investigation of pregnancy outcome and ovarian hyper stimulation syndrome prevention in agonist and antagonist gonadotropin-releasing hormone protocol

BACKGROUND Given the controversies regarding the effectiveness of gonadotropin-releasing hormone (GnRH) antagonists in prevention of ovarian hyper stimulation syndrome stimulation, this study was designed to compare GnRH agonist protocol with GnRH antagonist protocol in patients who were candidate for assisted reproductive techniques (ARTs). MATERIALS AND METHODS This investigation was perfor...

متن کامل

P-165: Results of Adding Recombinant LH in Normoresponder Patients for Assisted Reproductive Technology Treatment: A Prospective Randomized Control Trial

Background: Based on classical two cell- two-gonadotropin theory, in the follicle, FSH and LH put on their main effects on the granulosa and theca cells. LH is essential for androgens production. Androgens as precursor, is used for estradiol production by granulosa cells under aromatase activity. Profound suppression of LH concentrations in some normogonadotropic patients can cause several adve...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Expert opinion on drug metabolism & toxicology

دوره 5 10  شماره 

صفحات  -

تاریخ انتشار 2009